Journal
RHEUMATOLOGY
Volume 58, Issue -, Pages 4-16Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/key432
Keywords
cytokines; signal transduction; Janus kinases; kinase inhibitors; autoimmunity; inflammation
Categories
Funding
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Intramural Research Program
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001251] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041106, ZICAR041181, ZIAAR041159] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cytokines are critical mediators of diverse immune and inflammatory diseases. Targeting cytokines and cytokine receptors with biologics has revolutionized the treatment of many of these diseases, but targeting intracellular signalling with Janus kinase (JAK) inhibitors (jakinibs) now represents a major new therapeutic advance. We are still in the first decade since these drugs were approved and there is still much to be learned about the mechanisms of action of these drugs and the practical use of these agents. Herein we will review cytokines that do, and just as importantly, do not signal by JAKs, as well as explain how this relates to both efficacy and side effects in various diseases. We will review new, next-generation selective jakinibs, as well as the prospects and challenges ahead in targeting JAKs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available